C WorldWide Group Holding A S Has $13.98 Million Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

C WorldWide Group Holding A S grew its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 33.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 400,000 shares of the company's stock after buying an additional 100,000 shares during the quarter. C WorldWide Group Holding A S owned approximately 0.25% of Ionis Pharmaceuticals worth $13,984,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in IONS. Creative Planning grew its stake in shares of Ionis Pharmaceuticals by 5.7% in the 3rd quarter. Creative Planning now owns 28,382 shares of the company's stock valued at $1,137,000 after buying an additional 1,522 shares in the last quarter. International Assets Investment Management LLC grew its stake in shares of Ionis Pharmaceuticals by 3,287.0% in the 3rd quarter. International Assets Investment Management LLC now owns 328,772 shares of the company's stock valued at $13,171,000 after buying an additional 319,065 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Ionis Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,288 shares of the company's stock valued at $216,000 after buying an additional 930 shares in the last quarter. abrdn plc grew its stake in shares of Ionis Pharmaceuticals by 22.8% in the 3rd quarter. abrdn plc now owns 303,274 shares of the company's stock valued at $12,064,000 after buying an additional 56,357 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Ionis Pharmaceuticals by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 28,121 shares of the company's stock valued at $1,127,000 after buying an additional 10,971 shares in the last quarter. Institutional investors own 93.86% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on IONS. William Blair reiterated an "outperform" rating on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. Citigroup lowered their price target on Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Piper Sandler reduced their price objective on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. BMO Capital Markets decreased their price objective on shares of Ionis Pharmaceuticals from $60.00 to $45.00 and set a "market perform" rating for the company in a report on Thursday, February 20th. Finally, Wells Fargo & Company cut their target price on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating for the company in a research report on Thursday, November 7th. Two analysts have rated the stock with a sell rating, five have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $60.00.

Insider Transactions at Ionis Pharmaceuticals

In other news, Director Michael R. Hayden bought 5,000 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, December 23rd. The shares were bought at an average price of $36.22 per share, for a total transaction of $181,100.00. Following the purchase, the director now owns 35,219 shares of the company's stock, valued at approximately $1,275,632.18. This trade represents a 16.55 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Patrick R. O'neil sold 6,165 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $31.62, for a total transaction of $194,937.30. Following the sale, the executive vice president now owns 57,452 shares of the company's stock, valued at $1,816,632.24. This trade represents a 9.69 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 111,816 shares of company stock valued at $3,603,914. Corporate insiders own 2.71% of the company's stock.

Ionis Pharmaceuticals Stock Performance

IONS traded down $0.41 during trading on Thursday, reaching $31.35. 840,634 shares of the company's stock were exchanged, compared to its average volume of 1,661,325. The company has a market capitalization of $4.98 billion, a P/E ratio of -10.31 and a beta of 0.34. The company has a quick ratio of 8.82, a current ratio of 8.47 and a debt-to-equity ratio of 2.12. The business has a 50 day moving average price of $33.23 and a 200 day moving average price of $37.94. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $30.23 and a fifty-two week high of $52.34.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last posted its earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, beating analysts' consensus estimates of ($1.12) by $0.46. The business had revenue of $227.00 million for the quarter, compared to analysts' expectations of $140.97 million. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The firm's revenue for the quarter was down 30.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.12 earnings per share. As a group, analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.